UPDATE: Deutsche Bank Reiterates Hold, $14 PT on Amylin Pharmaceuticals on Uncertainty for Takeout Bid
Deutsche Bank maintains its Hold rating and $14 price target on Amylin Pharmaceuticals (NASDAQ: AMLN) as takeout offer from Bristol Myers Squibb develops.
Deutsche Bank comments, "Based on weekly IMS TRx, we see following trends: 1) GLP-1 market continues to grow, 2) Bydureon taking share from Byetta, not Victoza & 3) Bydureon growing but behind Victoza launch pace. …We note AMLN shares are trading well above our TP of $14 due to an unconfirmed takeout bid from Bristol Myers Squibb of $22 (Source: Bloomberg Finance LP). We are maintaining Hold rating given the deal is still unconfirmed and shares can pull back if bidder leaves the table."
AMLN closed at $27.96 on Friday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.